"We Want to Double our Sales Within Three Years"
BILLERBECK, Germany, October 10 /PRNewswire/ -- With an increase in sales of EUR 3.4 million to EUR 17 million, Dr. Suwelack Skin & Health Care AG is still on the path of significant growth in 2007. "We want to increase our sales to EUR 30 million within three years," states CEO Nikolaus Uleer. With the construction of the largest pharmaceutical-standard production plant in the world, the biotech manufacturer has considerably expanded its activities.
The German biotech manufacturer earns 80 percent of its sales abroad, with the most significant growth in the USA - within one year, its Puracol dressing for chronic wounds has successfully competed against similar products. A second wound dressing is currently undergoing the FDA certification process.
Uleer regards the progress made with the European introduction of the collagen and elastic based biomatrix Matriderm as at least equal in significance to the successes on the US market. Surgeons implant Matriderm as a dermis replacement for the treatment of deep burn wounds. Says Uleer: "With an equity to assets ratio of 70 percent, the company is well-prepared for the international introduction of other medical products."
However: About 80 percent of international sales are in the cosmetics sector. International cosmetics companies implement their facial mask systems, and the major consumers are in Japan, Hong Kong and Germany. Regarding the objectives, Uleer explains: "Our product expertise has not yet been generally recognized, but we are seriously working on this. We intend to gain synergies from the latest scientific research in the medical and cosmetics fields and use these for product development."
Grossbeerenstrasse 28 c
10965 Berlin, Germany
|SOURCE Dr. Suwelack Skin & Health Care AG|
Copyright©2007 PR Newswire.
All rights reserved